Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 10 versus ORETON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 10 versus ORETON.
ANDROID 10 vs ORETON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Androgen receptor agonist; binds to androgen receptors, stimulating protein synthesis, growth of male reproductive tissues, and development of secondary sexual characteristics.
Testosterone undecanoate 750 mg (3 mL) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
Testosterone enanthate 50-400 mg IM every 2-4 weeks.
None Documented
None Documented
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
8 hours for testosterone; clinical context: requires daily or weekly dosing for replacement therapy
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Renal (90% as metabolites, 5% unchanged), biliary/fecal (10%)
Category C
Category C
Androgen
Androgen